Cancundude.....I think you know enough.  My feeling is that we've pretty much bottomed out in this current range.  If the price does go much lower it will be a great buying opportunity this close to topline..IMO.  After all, we're only a few weeks away and any further discussion on whether this goes much past $4 will be a moot point if topline is positive.  There have been less than 2M shares traded since the PO was announced which isn't a whole lot given the number of shares outstanding. Further, half of that trading took place the day after the announcement. True, most of those shares are privately held but it's still not a huge number.  I really don't think many people know about RVX outside of those folks that follow biotech.  But if the news is positive the word will surely get out and that is what will drive the SP to new heights.  

I know that we've touched on this in past posts, but I would find it hard to believe that based on such strong RRR numbers coming out of the P2 trials for the targeted patient groups that P3 wouldn't at the very least produce a notable result.  Otherwise P2 will have really been out to lunch....which is of course possible, but I doubt it.  Also, RVX now has funding for the PAH P2 trial which could, if successful, also provide a bit of a backstop for the share price down the road should P3 results prove less than stellar.  Gains are awesome but we also want to protect what is currently invested, and any initiatives that can help do that is welcome.

What's the conventional saying now?  Oh yes........tic toc.